An observational study in Hyperkalemia, End-Stage Kidney Disease (ESKD) and Hemodialysis, sponsored by Chungnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Chungnam National University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Hyperkalemia is a common and potentially fatal electrolyte disorder in patients receiving maintenance hemodialysis, but it is currently detected only by periodic blood tests. This prospective, single-center observational cohort study will evaluate whether T-wave morphology measured with a six-channel wearable electrocardiogram (ECG) patch can identify hyperkalemia (serum potassium greater than 5.0 mEq/L) in these patients. Forty adults on thrice-weekly hemodialysis will wear the device during one dialysis session per month for 6 months. ECG recordings will be compared with serum potassium measured before and after the same dialysis session. No treatment is assigned by the study, and no additional blood draws are required.
Patients on maintenance hemodialysis accumulate potassium between sessions, and hyperkalemia can cause conduction delay, bradycardia, ventricular arrhythmia, and cardiac arrest, often without symptoms. Routine monitoring relies on monthly venous blood sampling and cannot capture changes between tests. Previous studies have shown that T-wave morphology on the ECG correlates with serum potassium, but most wearable studies have used single-lead signals.
The investigators previously conducted a pilot study (NCT07054905) in 32 hemodialysis patients using a single-lead wearable ECG patch over 6 weeks with pre-dialysis potassium only. The present study extends that design in three ways: (1) a wearable device that records six ECG channels from three chest electrodes, (2) a longer observation period of 6 months with one measurement session per month (6 sessions per participant), and (3) measurement of post-dialysis potassium, calcium, and phosphate in addition to pre-dialysis laboratory tests, so that ECG changes can be related to the large electrolyte shift within a single dialysis session.
At each monthly session, scheduled on the day of the routine monthly blood test, the device is attached immediately before dialysis, records continuously throughout dialysis, and is removed at the end of the session. Pre-dialysis laboratory values are taken from routine monthly tests. Post-dialysis potassium, calcium, and phosphate are measured in the blood sample routinely drawn for dialysis adequacy assessment. Dialysis prescription, intradialytic blood pressure, body weight, medication changes, and skin condition at the attachment site are recorded at each session. Dialysis prescriptions and medications are determined by the treating physicians and are not specified by the study.
ECG waveform indices (including T-wave amplitude, slope, slope-to-amplitude ratio, QRS duration, QT and corrected QT intervals, PR interval, and P-wave amplitude) are calculated for each channel. The primary analysis evaluates discrimination of pre-dialysis hyperkalemia using mixed-effects logistic regression with a random effect for participant, with confidence intervals obtained by participant-level bootstrap. Secondary analyses use linear mixed-effects models and repeated-measures correlation to estimate within-participant associations. The study is exploratory; the sample size of 40 participants (240 sessions) was chosen based on prior studies of similar design, expected precision of the primary estimate, and feasibility. Results will provide effect size and intraclass correlation estimates for planning a subsequent multicenter confirmatory study.
134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.
This study's planned enrollment of 40 is below the median of 459 across 30 observational studies indexed under Hyperkalemia.
Browse Hyperkalemia studies →Chungnam National University Hospital is the lead sponsor of 22 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults with end-stage kidney disease receiving maintenance hemodialysis at the hemodialysis unit of Chungnam National University Hospital, Daejeon, Republic of Korea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults receiving thrice-weekly maintenance hemodialysis at a single center who wear a six-channel wearable ECG patch during one dialysis session per month for 6 months.
Device: Six-channel wearable ECG patch (SHC-U8)
A wearable Holter-type ECG recorder (model SHC-U8, Solmitech Co., Ltd., Republic of Korea) that records six ECG channels from three chest electrodes. The device is attached immediately before dialysis and removed at the end of the session, once per month for 6 months. It is used within its approved indication for ECG recording only; no treatment is assigned.
Area under the receiver operating characteristic curve (AUC) of the pre-dialysis T-wave morphology index for discriminating hyperkalemia
Hyperkalemia is defined as pre-dialysis serum potassium greater than 5.0 mEq/L. The prespecified T-wave morphology index (T-wave slope-to-amplitude ratio) is calculated from the six-channel wearable ECG recorded immediately before dialysis. AUC is estimated from a mixed-effects logistic regression model with a random effect for participant; the 95% confidence interval is obtained by participant-level bootstrap.
Time frame: At each monthly dialysis session for 6 months (6 sessions per participant)
Within-participant correlation between the T-wave morphology index and serum potassium concentration
Estimated from a linear mixed-effects model separating between- and within-participant associations, using pre- and post-dialysis measurements.
Time frame: At each monthly dialysis session for 6 months (6 sessions per participant)
Mean absolute error of ECG-estimated serum potassium
Mean absolute error (mEq/L) between ECG-based estimated potassium and laboratory serum potassium, with participant-level cross-validation.
Time frame: At each monthly dialysis session for 6 months (6 sessions per participant)
Within-participant correlation between change in serum potassium and change in ECG indices during dialysis
Repeated-measures correlation between the pre- to post-dialysis change in serum potassium (mEq/L) and the corresponding change in ECG waveform indices within the same session.
Time frame: At each monthly dialysis session for 6 months (6 sessions per participant)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Nov 2027, 12 months after the start.
Of 20 observational studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chungnam National University Hospital